NEW YORK (GenomeWeb News) — Osmetech will use Epidauros Biotechnologies’ CYP450 2D6 biomarker patent to expand into pharmacogenomics testing, the companies said today.
 
The diagnostic healthcare company has signed a non-exclusive licensing agreement to use the IP to the genetic variant 2988G>A, which it will use in combination with other variants as predictive markers in its molecular and critical care diagnostic ventures.
 
Financial details were not disclosed.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers have sequenced the northern white rhinoceros to gauge whether it could be brought back from the edge of extinction, the New York Times reports.

Bavaria expands its forensic genetic analyses to include DNA phenotyping, raising discrimination concerns.

Tufts University researchers found a role for miRNA in transmitting stress between generations, the Economist reports.

In Science this week: gut microbiome influences liver cancer growth, spread; and more.

Jun
19
Sponsored by
Advanced Cell Diagnostics

This webinar will provide evidence for the use of RNA in situ hybridization (RNA ISH) as a replacement for immunohistochemistry (IHC) in cancer research and diagnostic applications.

Jun
21
Sponsored by
Roche

This webinar will provide a detailed look at how a genomics lab implemented next-generation sequencing (NGS) liquid biopsy assays into its in-house clinical research program.